← All Companies
Zymeworks Inc.
ZYME · Nasdaq · SIC 2834: Pharmaceutical Preparations
Business Summary PART I Overview Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat conditions, including cancer, inflammation, and autoimmune disease. We believe our asset and royalty aggregation strategy differentiates us from other biotechnology companies because it provides us with an opportunity to optimize future milestone and royalty...
Next Earnings Q2 FY2026 — expected 2026-09-06
Key Facts from Earnings Calls Type Subject Detail Quarter topic_mention ZYME discussed_in_filing Cybersecurity topic_mention ZYME discussed_in_filing Trusted Computing topic_mention ZYME discussed_in_filing Blockchain & Crypto topic_mention ZYME discussed_in_filing Capital Expenditure topic_mention ZYME discussed_in_filing Regulation topic_mention ZYME discussed_in_filing Healthcare & Bio topic_mention ZYME discussed_in_filing Platform & Ecosystem topic_mention ZYME discussed_in_filing Sovereign & Government topic_mention ZYME discussed_in_filing Cybersecurity topic_mention ZYME discussed_in_filing Trusted Computing topic_mention ZYME discussed_in_filing Blockchain & Crypto topic_mention ZYME discussed_in_filing Capital Expenditure topic_mention ZYME discussed_in_filing Regulation topic_mention ZYME discussed_in_filing Healthcare & Bio topic_mention ZYME discussed_in_filing Platform & Ecosystem topic_mention ZYME discussed_in_filing Sovereign & Government topic_mention ZYME discussed_in_filing Cybersecurity topic_mention ZYME discussed_in_filing Trusted Computing topic_mention ZYME discussed_in_filing Blockchain & Crypto topic_mention ZYME discussed_in_filing Capital Expenditure
Annual Reports (10-K) Filed Period Accession Source Full Text 2026-03-02 2025-12-31 0001937653-26-000015 EDGAR 115K words 2025-03-05 2024-12-31 0001937653-25-000014 EDGAR — 2024-03-06 2023-12-31 0001937653-24-000019 EDGAR — 2023-03-07 2022-12-31 0001937653-23-000011 EDGAR —
Quarterly Reports (10-Q) Filed Period Accession Source Full Text 2025-11-06 2025-09-30 0001937653-25-000077 EDGAR 65K words 2025-08-07 2025-06-30 0001937653-25-000049 EDGAR — 2025-05-08 2025-03-31 0001937653-25-000027 EDGAR — 2024-10-31 2024-09-30 0001937653-24-000050 EDGAR — 2024-08-01 2024-06-30 0001937653-24-000041 EDGAR — 2024-05-02 2024-03-31 0001937653-24-000028 EDGAR — 2023-11-07 2023-09-30 0001937653-23-000037 EDGAR — 2023-08-10 2023-06-30 0001937653-23-000028 EDGAR — 2023-05-08 2023-03-31 0001937653-23-000018 EDGAR — 2022-11-08 2022-09-30 0001937653-22-000009 EDGAR —
Recent Current Reports (8-K) Filed Accession Source Full Text 2026-04-01 0001193125-26-135610 EDGAR 12K words 2026-03-02 0001193125-26-084082 EDGAR — 2026-03-02 0001937653-26-000013 EDGAR — 2026-01-12 0001193125-26-010480 EDGAR — 2025-12-30 0001193125-25-337268 EDGAR — 2025-11-18 0001193125-25-285259 EDGAR — 2025-11-17 0001193125-25-283873 EDGAR — 2025-11-06 0001937653-25-000076 EDGAR — 2025-09-02 0001193125-25-193351 EDGAR — 2025-08-11 0001193125-25-177505 EDGAR —
100 total filings indexed. 76 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
Sector Peers Company Identity
CIK 0001937653
Ticker ZYME
Exchange Nasdaq
SIC 2834: Pharmaceutical Preparations
Incorporated DE
Get More Data
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile
Stock Quote
AI Readiness Report
Origin Provenance
page leaf: bf6654b8f04433b4cf52242f343a71e079b6e224220d19f111bfd0caf50eaa1b
parent: 9f01c46cfb30efb25ee5e672b75d675ca08ec3321d429c8dca6812e317b61698
content hash: 2a3467e176bcfc4be9125a04260937e72a02df00e3c7e7a5e1ed60916c013dd5
signed: 2026-04-13T04:48:24.278Z
sources: 14 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf